CN116626195A - 一种硝酸异山梨酯注射液中硝酸盐和亚硝酸盐含量的检测方法 - Google Patents
一种硝酸异山梨酯注射液中硝酸盐和亚硝酸盐含量的检测方法 Download PDFInfo
- Publication number
- CN116626195A CN116626195A CN202310597703.6A CN202310597703A CN116626195A CN 116626195 A CN116626195 A CN 116626195A CN 202310597703 A CN202310597703 A CN 202310597703A CN 116626195 A CN116626195 A CN 116626195A
- Authority
- CN
- China
- Prior art keywords
- solution
- reference substance
- sodium nitrite
- isosorbide dinitrate
- potassium nitrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 title claims abstract description 22
- 229960000201 isosorbide dinitrate Drugs 0.000 title claims abstract description 22
- 229910002651 NO3 Inorganic materials 0.000 title claims abstract description 17
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 238000002347 injection Methods 0.000 title claims abstract description 16
- 239000007924 injection Substances 0.000 title claims abstract description 16
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical group CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000741 silica gel Substances 0.000 claims abstract description 5
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 83
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 77
- 235000010288 sodium nitrite Nutrition 0.000 claims description 41
- 239000000243 solution Substances 0.000 claims description 39
- 235000010333 potassium nitrate Nutrition 0.000 claims description 38
- 239000004323 potassium nitrate Substances 0.000 claims description 38
- 239000011550 stock solution Substances 0.000 claims description 32
- 239000013558 reference substance Substances 0.000 claims description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 9
- 238000007865 diluting Methods 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 239000012085 test solution Substances 0.000 claims description 5
- 239000012488 sample solution Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 239000003085 diluting agent Substances 0.000 description 27
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 239000012467 final product Substances 0.000 description 10
- 239000012535 impurity Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- 229940094124 isosorbide dinitrate 0.5 mg/ml Drugs 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
本发明公开了一种硝酸异山梨酯注射液中硝酸盐和亚硝酸盐含量的检测方法,本方法无需特殊的仪器设备,采用常见的搭载十八烷基硅烷键合硅胶柱的高效液相色谱仪进行检测。此方法经过验证符合标准,准确可靠,实用性强,可以直接应用于硝酸异山梨酯注射液的生产质量监测。
Description
技术领域
本发明涉及药物分析领域,具体涉及一种硝酸异山梨酯注射液中硝酸盐和亚硝酸盐含量的检测方法。
背景技术
硝酸异山梨酯(isosorbide dinitrate)是一种硝酸酯类血管扩张药,其化学名为[(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]nitrate,主要药理作用是松弛血管平滑肌。总的效应是使心肌耗氧量减少,供氧量增多,心绞痛得以缓解。临床可用于治疗各种类型冠心病心绞痛和预防发作。静脉滴注可用于治疗充血性心衰。
目前常见的硝酸异山梨酯的生产合成工艺较为成熟,路线中最核心的步骤是使用硫酸和硝酸制成的混酸进行异山梨醇的硝酸酯化反应。这个工艺条件选择性较差,容易产生各种杂质。此外硝酸异山梨酯自身也会发生降解,导致最终产品中混入硝酸盐以及亚硝酸盐类杂质。目前药典以及ICH指导原则都有对药物杂质的含量限度作出要求。一般对于无特殊基因毒性的单项杂质,其鉴定限为0.1%。对于有潜在基因毒性的结构,则应该根据ICHM7中基因毒性杂质TTC进行计算,进行含量控制。在现有公开技术中,《中国药典》记载了硝酸异山梨酯中硝酸盐杂质的检测方法,采用呈色反应进行检测,无法进行准确定量检查;JX20160056进口注册标准、ChP2020版和BP2022标准等几个规范中记载了亚硝酸盐杂质的分析方法,均为紫外分光光度法进行半定量检查,不够准确;耿玮等发表的文章(《中国药事》2014年第28卷第7期,783-786页)记载了使用离子色谱法测定硝酸异山梨酯注射剂中硝酸盐以及亚硝酸盐含量的方法,但其需要用到专用的离子色谱柱以及相关仪器,设备通用性不高且操作较为繁琐。
发明内容
基于上述技术背景,我们在本发明中提供了一种检测硝酸异山梨酯注射液中硝酸盐和亚硝酸盐含量的方法,本方法无需特殊的仪器设备,采用常见的搭载十八烷基硅烷键合硅胶柱的高效液相色谱仪进行检测。此方法经过验证符合标准。该检测方法的具体内容包括如下步骤:
(1)溶液配制
稀释液/空白溶液:0.02% NaOH溶液
亚硝酸钠对照品储备液:取亚硝酸钠对照品约24mg,精密称定,置250ml量瓶中,用稀释液溶解并稀释至刻度。
硝酸钾对照品储备液:取硝酸钾对照品约31mg,精密称定,置50ml量瓶中,用稀释液溶解并稀释至刻度。
对照品溶液:精密量取亚硝酸钠对照品储备液2ml和硝酸钾对照品储备液1ml,置250ml量瓶中,用0.02% NaOH水溶液稀释并定容至刻度。
灵敏度溶液:精密量取对照品溶液5ml,置10ml量瓶中,加稀释液稀释并定容至刻度。
供试品溶液:精密量取硝酸异山梨酯注射液,用0.02% NaOH水溶液溶解稀释,配制成硝酸异山梨酯浓度为0.5mg/ml的溶液。
(2)进样:待系统稳定后,进稀释液1针,灵敏度溶液1针,对照品溶液6针,供试品溶液1针,在序列完成前再进对照品溶液1针,若运行时间超过8小时,则需每隔8小时再进对照品溶液1针,记录色谱图并进行计算;色谱条件为:采用十八烷基硅烷键合硅胶柱WelchUltimate® OAA,4.6 mm×300mm,5μm,柱温30 ℃;采用紫外检测器,检测波长210 nm;采用混合流动相,梯度洗脱,流动相A是体积比为90:10的0.1%磷酸溶液与乙腈的混合液,流动相B是乙腈,流速1.0 ml/min;洗脱梯度为:
得到的结果按照如下公式计算:
亚硝酸盐含量计算公式:
其中:
Aspl——供试品溶液中亚硝酸根峰面积
Astd——6针对照品溶液中亚硝酸根的平均峰面积
Wstd——对照品溶液中亚硝酸钠的取样量(mg)
P——亚硝酸钠对照品含量
Vspl——供试品溶液稀释倍数
Vstd——对照品溶液中亚硝酸钠的稀释倍数
46.01/69.00——亚硝酸根与亚硝酸钠的折算系数(亚硝酸根相对分子质量为46.01,亚硝酸钠相对分子质量为69.00)
杂质含量单位:%(g/ml)(表示溶液100ml中含有溶质若干克);
硝酸盐含量计算公式:
其中:
Aspl——供试品溶液中硝酸根峰面积
Astd——6针对照品溶液中硝酸根的平均峰面积
Wstd——对照品溶液中硝酸钾的取样量(mg)
P——硝酸钾对照品含量
Vspl——供试品溶液稀释倍数
Vstd——对照品溶液中硝酸钾的稀释倍数
62.00/101.10——硝酸根与硝酸钾的折算系数(硝酸根相对分子质量为62.00,硝酸钾相对分子质量为101.10)
杂质含量单位:%(g/ml)(表示溶液100ml中含有溶质若干克);
有益效果:提供了一种利用常规搭载十八烷基硅烷键合硅胶柱的高效液相色谱法检测硝酸异山梨酯注射液中硝酸盐和亚硝酸盐杂质的方法。此方法无需使用离子色谱仪等仪器设备,准确可靠,实用性强,可以直接应用于硝酸异山梨酯注射液的生产质量监测。
实施方式
实施例1
线性实验
硝酸钾储备液:精密称取硝酸钾96.04mg,置200ml量瓶中,加稀释剂溶解并稀释至刻度,摇匀,即得。
亚硝酸钠储备液:精密称取亚硝酸钠30.40mg,置200ml量瓶中,加稀释剂溶解并稀释至刻度,摇匀,即得。
线性储备液:精密移取硝酸钾储备液5ml和亚硝酸钠储备液5ml,置100ml量瓶中,加稀释剂稀释并定容至刻度,摇匀即得。
将上述溶液分别进样至高效液相色谱仪中,并进行计算;色谱条件为:采用十八烷基硅烷键合硅胶柱Welch Ultimate® OAA,4.6 mm×300mm,5μm,柱温30 ℃;采用紫外检测器,检测波长210 nm;采用混合流动相梯度洗脱,流动相A是体积比90:10的0.1%磷酸溶液-乙腈混合液,流动相B是乙腈,流速1.0 ml/min;洗脱梯度为:
。
实验结果:
实施例2
准确度实验
硝酸钾储备液:精密称取硝酸钾96.04mg,置200ml量瓶中,加稀释剂溶解并稀释至刻度,摇匀,即得。(硝酸钾浓度 294.7762μg/ml)
亚硝酸钠储备液:精密称取亚硝酸钠30.40mg,置200ml量瓶中,加稀释剂溶解并稀释至刻度,摇匀,即得。(亚硝酸钠浓度 101.3333μg/ml)
对照品溶液:精密移取硝酸钾储备液1ml和亚硝酸钠储备液1ml,置200ml量瓶中,加稀释剂稀释并定容至刻度,摇匀即得。(硝酸钾浓度 1.4739μg/ml, 亚硝酸钠浓度0.5066μg/ml)
准确度储备液:精密移取硝酸钾储备液5ml和亚硝酸钠储备液5ml,置100ml量瓶中,加稀释剂稀释并定容至刻度,摇匀即得。(硝酸根浓度 14.7388μg/ml, 亚硝酸钠浓度5.0667μg/ml)
准确度溶液:按下表分别量取准确度储备液,加硝酸异山梨酯注射液(10ml:10mg)稀释至刻度,摇匀,再精密移取5ml,置10ml量瓶中,加稀释剂稀释并定容至刻度,摇匀即得。每个准确度溶液平行配制三份。
将上述溶液进样,色谱条件同实施例1
结果:
实施例3
样品检测
亚硝酸钠对照品储备液:取亚硝酸钠对照品约24mg,精密称定,置250ml量瓶中,用稀释液溶解并稀释至刻度,摇匀。(亚硝酸钠64µg/ml)
硝酸钾对照品储备液:取硝酸钾对照品约31mg,精密称定,置50ml量瓶中,用稀释液溶解并稀释至刻度,摇匀。(硝酸钾380µg/ml)
对照品溶液:精密量取亚硝酸钠对照品储备液2ml和硝酸钾对照品储备液1ml,置250ml量瓶中,加稀释液稀释并定容至刻度,摇匀。(亚硝酸钠0.5µg/ml ,硝酸钾1.5µg/ml)
灵敏度溶液:精密量取对照品溶液5ml,置10ml量瓶中,加稀释液稀释并定容至刻度,摇匀。(亚硝酸钠0.25µg/ml,硝酸钾0.75µg/ml)
供试品溶液:精密量取硝酸异山梨酯注射液5ml,置10ml量瓶中,用稀释液稀释并定容至刻度,摇匀。(硝酸异山梨酯0.5mg/ml)
待系统稳定后,进稀释液1针,灵敏度溶液1针,对照品溶液6针,供试品溶液1针,在序列完成前再进对照品溶液1针,记录色谱图。色谱条件同实施例1。
检测结果
实施例4
系统适用性实验
硝酸钾储备液:精密称取硝酸钾96.04mg,置200ml量瓶中,加稀释剂溶解并稀释至刻度,摇匀,即得。(硝酸钾浓度 294.7762μg/ml)
亚硝酸钠储备液:精密称取亚硝酸钠30.40mg,置200ml量瓶中,加稀释剂溶解并稀释至刻度,摇匀,即得。(亚硝酸钠浓度 101.3333μg/ml)
对照品溶液:精密移取硝酸钾储备液1ml和亚硝酸钠储备液1ml,置200ml量瓶中,加稀释剂稀释并定容至刻度,摇匀即得。(硝酸钾浓度 1.4739μg/ml, 亚硝酸钠浓度0.5066μg/ml)
将上述溶液进样,色谱条件同实施例1
结果:
实施例5
定量限与检测限实验
硝酸钾储备液:精密称取硝酸钾96.04mg,置200ml量瓶中,加稀释剂溶解并稀释至刻度,摇匀,即得。(硝酸钾浓度 294.7762μg/ml)
亚硝酸钠储备液:精密称取亚硝酸钠30.40mg,置200ml量瓶中,加稀释剂溶解并稀释至刻度,摇匀,即得。(亚硝酸钠浓度 101.3333μg/ml)
定量限储备液:精密移取硝酸钾储备液5ml和亚硝酸钠储备液5ml,置100ml量瓶中,加稀释剂稀释并定容至刻度,摇匀即得。(硝酸钾浓度 14.7388μg/ml, 亚硝酸钠浓度5.0667μg/ml)
定量限溶液:精密移取定量限储备液3ml,置200ml量瓶中,加稀释剂稀释并定容至刻度,摇匀即得。(硝酸钾浓度 0.2211μg/ml, 亚硝酸钠浓度 0.0760μg/ml)
检测限溶液:精密移取定量限溶液5ml,置10ml量瓶中,加稀释剂稀释并定容至刻度,摇匀即得。(硝酸钾浓度 0.1101μg/ml, 亚硝酸钠浓度 0.0380μg/ml)
将上述溶液进样,色谱条件同实施例1
结果:
/>
Claims (2)
1.一种检测硝酸异山梨酯注射液中硝酸盐和亚硝酸盐含量的方法,其特征在于,包括以下步骤:
供试品溶液配制:精密量取硝酸异山梨酯注射液,用0.02% NaOH水溶液溶解稀释,配制成硝酸异山梨酯浓度为0.5mg/ml的溶液;
对照品溶液配制:取亚硝酸钠对照品24mg,置250ml量瓶中,用0.02% NaOH水溶液溶解并稀释定容至刻度,得到亚硝酸钠对照品储备液;取硝酸钾对照品约31mg,精密称定,置50ml量瓶中,用0.02% NaOH水溶液溶解并稀释定容至刻度,得到硝酸钾对照品储备液;精密量取亚硝酸钠对照品储备液2ml和硝酸钾对照品储备液1ml,置250ml量瓶中,用0.02% NaOH水溶液稀释并定容至刻度,得到对照品溶液;
将对照品溶液和供试品溶液分别进样至高效液相色谱仪中,记录图谱;色谱条件为:采用十八烷基硅烷键合硅胶柱,4.6 mm×300mm,5μm,柱温30 ℃;采用紫外检测器,检测波长210 nm;采用混合流动相梯度洗脱,流动相A是体积比为90:10的0.1%磷酸溶液与乙腈的混合液,流动相B是乙腈,流速1.0 ml/min。
2.如权利要求1所述方法,所述梯度洗脱的梯度为:
。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310597703.6A CN116626195A (zh) | 2023-05-25 | 2023-05-25 | 一种硝酸异山梨酯注射液中硝酸盐和亚硝酸盐含量的检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310597703.6A CN116626195A (zh) | 2023-05-25 | 2023-05-25 | 一种硝酸异山梨酯注射液中硝酸盐和亚硝酸盐含量的检测方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116626195A true CN116626195A (zh) | 2023-08-22 |
Family
ID=87636200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310597703.6A Pending CN116626195A (zh) | 2023-05-25 | 2023-05-25 | 一种硝酸异山梨酯注射液中硝酸盐和亚硝酸盐含量的检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116626195A (zh) |
-
2023
- 2023-05-25 CN CN202310597703.6A patent/CN116626195A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110672734B (zh) | 一种盐酸胺碘酮注射液中有关物质的分析方法 | |
CN111398475A (zh) | 一种用高效液相色谱法分析硫酸羟氯喹制剂组成的方法 | |
CN113049687B (zh) | 一种盐酸氨溴索原料和注射液有关物质的检测方法 | |
CN112526017A (zh) | 用hplc法检测氨美愈素复方制剂中多种杂质含量的方法 | |
CN113702514A (zh) | 一种阿托伐他汀钙有关杂质ⅰ的测定方法 | |
CN116626195A (zh) | 一种硝酸异山梨酯注射液中硝酸盐和亚硝酸盐含量的检测方法 | |
CN114324642B (zh) | 一种氢溴酸右美沙芬有关物质的测定方法 | |
CN109030653B (zh) | 一种左亚叶酸中有关物质的检测方法 | |
CN114689737B (zh) | 一种s-邻氯苯甘氨酸甲酯酒石酸盐有关物质的分析方法 | |
CN112611813B (zh) | 一种沙库巴曲缬沙坦钠起始物料的基因毒杂质测试方法 | |
CN110412164B (zh) | 一种盐酸美西律的有关物质的检测方法 | |
CN113848271A (zh) | 一种检测盐酸左西替利嗪口服溶液中有关物质的方法 | |
CN114354788B (zh) | 一种Molnupiravir原料及其制剂中有关物质的测定方法 | |
CN109283263B (zh) | 用于雷替曲塞合成质量控制的检测分析方法 | |
CN110749692A (zh) | L-谷氨酸二乙酯盐酸盐及其光学异构体的分离检测方法 | |
CN111426773B (zh) | 高效液相色谱法检测盐酸胺碘酮中的碘化物杂质 | |
CN117269357B (zh) | 一种测定阿加曲班中杂质c的检测方法 | |
CN113419006B (zh) | 一种阿瑞匹坦光学异构体的液相分析方法 | |
CN114280169B (zh) | 一种莫那比拉韦中异构体的测定方法 | |
CN114487148B (zh) | 一种基因毒杂质的检测方法 | |
CN114518423B (zh) | 一种用于检测盐酸多巴胺注射液中杂质的方法 | |
CN116751185A (zh) | 一种三唑类化合物制剂中的杂质及该杂质的制备方法、检测方法和应用 | |
CN107091895B (zh) | 采用hplc分离测定利奥西呱原料药中有关物质的方法 | |
CN118169258A (zh) | 一种盐酸环维黄杨星d中有关物质的检测方法 | |
CN117110505A (zh) | 一种枸橼酸西地那非中基因毒性杂质的检测方法及质控限度 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |